DK3149019T3 - Cholan-derivater til anvendelse ved behandling og/eller forebyggelse af FXR- og TGR5/GPBAR1-formidlede sygdomme - Google Patents

Cholan-derivater til anvendelse ved behandling og/eller forebyggelse af FXR- og TGR5/GPBAR1-formidlede sygdomme Download PDF

Info

Publication number: DK3149019T3
Authority: DK; Denmark
Prior art keywords: gpbar1; cholan; tgr5; fxr; prevention
Prior art date: 2014-05-29

Application number

DK15731260.4T

Other languages

English (en)

Inventor

Angela Zampella

Stefano Fiorucci

Original Assignee

Bar Pharmaceuticals S R L

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-05-29

Filing date

2015-05-28

Publication date

2020-02-17

2015-05-28 Application filed by Bar Pharmaceuticals S R L filed Critical Bar Pharmaceuticals S R L

2020-02-17 Application granted granted Critical

2020-02-17 Publication of DK3149019T3 publication Critical patent/DK3149019T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J11/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 3
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Virology (AREA)
Toxicology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Obesity (AREA)
Hematology (AREA)
Endocrinology (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Urology & Nephrology (AREA)
Physical Education & Sports Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Rheumatology (AREA)
Neurology (AREA)
Orthopedic Medicine & Surgery (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
AIDS & HIV (AREA)
Neurosurgery (AREA)
Child & Adolescent Psychology (AREA)
Gastroenterology & Hepatology (AREA)
Vascular Medicine (AREA)
Dermatology (AREA)

DK15731260.4T 2014-05-29 2015-05-28 Cholan-derivater til anvendelse ved behandling og/eller forebyggelse af FXR- og TGR5/GPBAR1-formidlede sygdomme DK3149019T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
ITFI20140130		2014-05-29
PCT/EP2015/061802 WO2015181275A1 (en)	2014-05-29	2015-05-28	Cholane derivatives for use in the treatment and/or prevention of fxr and tgr5/gpbar1 mediated diseases

Publications (1)

Publication Number	Publication Date
DK3149019T3 true DK3149019T3 (da)	2020-02-17

Family

ID=51454763

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK15731260.4T DK3149019T3 (da)	2014-05-29	2015-05-28	Cholan-derivater til anvendelse ved behandling og/eller forebyggelse af FXR- og TGR5/GPBAR1-formidlede sygdomme
DK19204247.1T DK3626725T3 (da)	2014-05-29	2015-05-28	Cholan-derivater til anvendelse ved behandlingen og/eller forebyggelsen af fxr- og tgr5/gpbar1-medierede sygdomme

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK19204247.1T DK3626725T3 (da)	2014-05-29	2015-05-28	Cholan-derivater til anvendelse ved behandlingen og/eller forebyggelsen af fxr- og tgr5/gpbar1-medierede sygdomme

Country Status (25)

Country	Link
US (2)	US10407462B2 (da)
EP (2)	EP3149019B1 (da)
JP (1)	JP6820253B2 (da)
KR (1)	KR102491556B1 (da)
CN (2)	CN110003301B (da)
AU (1)	AU2015265893B2 (da)
CA (1)	CA2948585C (da)
CY (1)	CY1122631T1 (da)
DK (2)	DK3149019T3 (da)
EA (1)	EA032820B1 (da)
ES (2)	ES2938874T3 (da)
FI (1)	FI3626725T3 (da)
HR (2)	HRP20230170T1 (da)
HU (2)	HUE061506T2 (da)
LT (2)	LT3149019T (da)
MA (1)	MA39881B1 (da)
MX (2)	MX373721B (da)
PH (1)	PH12016502327A1 (da)
PL (2)	PL3626725T3 (da)
PT (2)	PT3626725T (da)
RS (2)	RS59910B1 (da)
SG (2)	SG10201809362RA (da)
SI (2)	SI3149019T1 (da)
SM (2)	SMT202300057T1 (da)
WO (1)	WO2015181275A1 (da)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2545964A1 (en)	2011-07-13	2013-01-16	Phenex Pharmaceuticals AG	Novel FXR (NR1H4) binding and activity modulating compounds
EP3149019B1 (en)	2014-05-29	2019-12-04	Bar Pharmaceuticals S.r.l.	Cholane derivatives for use in the treatment and/or prevention of fxr and tgr5/gpbar1 mediated diseases
CN106459136B (zh) *	2014-09-28	2018-06-26	江苏盛迪医药有限公司	一种奥贝胆酸的制备方法
HK1243930A1 (zh)	2014-11-06	2018-07-27	英安塔制药有限公司	作爲fxr/tgr5激动剂的胆汁酸类似物和其使用方法
CN111944006B (zh) *	2014-11-17	2021-12-17	正大天晴药业集团股份有限公司	新的7-酮-6β-烷基胆烷酸衍生物在制备奥贝胆酸以及其在医药领域的用途
CN107108688B (zh)	2014-11-19	2019-10-29	Nzp英国有限公司	作为制备类固醇FXR调节剂的中间体的6α-烷基-3,7-二酮类固醇
WO2016079518A1 (en)	2014-11-19	2016-05-26	Dextra Laboratories Limited	5.beta.-6-alkyl-7-hydroxy-3-one steroids as intermediates for the production of steroidal fxr modulators
TWI688571B (zh)	2014-11-19	2020-03-21	英商Ｎｚｐ英國有限公司	化合物（四）
PL3221331T3 (pl)	2014-11-19	2020-03-31	NZP UK Limited	Steroidy, 6-alkilo-7-hydroksy-4-en-3-ony jako związki pośrednie do wytwarzania steroidowych modulatorów fxr
US10208081B2 (en)	2014-11-26	2019-02-19	Enanta Pharmaceuticals, Inc.	Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
MX2017006833A (es)	2014-11-26	2018-02-13	Enanta Pharm Inc	Análogos de ácido biliar como agonistas de fxr/tgr5 y métodos para el uso de los mismos.
US11578097B2 (en)	2014-11-26	2023-02-14	Enanta Pharmaceuticals, Inc.	Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof
MX2017010376A (es)	2015-02-11	2017-12-20	Enanta Pharm Inc	Análogos de ácido biliar como agonistas de fxr/tgr5 y métodos para el uso de los mismos.
MX379579B (es)	2015-03-31	2025-03-11	Enanta Pharm Inc	Derivados de ácido biliar como agonistas de fxr/tgr5 y métodos para su uso.
US10800807B2 (en) *	2015-06-19	2020-10-13	Intercept Pharmaceuticals, Inc.	TGR5 modulators and methods of use thereof
US11072631B2 (en) *	2015-09-24	2021-07-27	Intercept Pharmaceuticals, Inc.	Methods and intermediates for the preparation bile acid derivatives
US10323061B2 (en)	2016-02-23	2019-06-18	Enanta Pharmaceuticals, Inc.	Heteroaryl containing bile acid analogs as FXR/TGR5 agonists and methods of use thereof
WO2017147159A1 (en) *	2016-02-23	2017-08-31	Enanta Pharmaceuticals, Inc.	Deuterated bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
WO2017147137A1 (en)	2016-02-23	2017-08-31	Enanta Pharmaceuticals, Inc.	Benzoic acid derivatives of bile acid as fxr/tgr5 agonists and methods of use thereof
CN108883305B (zh) *	2016-03-11	2021-03-16	英特塞普特医药品公司	3-脱氧衍生物及其药物组合物
CN105859817A (zh) *	2016-05-09	2016-08-17	成都宇西医药技术有限公司	一种制备3α-羟基-6-乙烯基-7-酮基-5β-胆烷酸的方法
GB201608777D0 (en)	2016-05-18	2016-06-29	Dextra Lab Ltd	Compounds
WO2017207648A1 (en)	2016-05-31	2017-12-07	Bionice, S.L.U	Process and intermediates for the preparation of obeticholic acid and derivatives thereof
CN109415405A (zh) *	2016-06-01	2019-03-01	雷迪博士实验室有限公司	制备奥贝胆酸的方法
EP3468962A1 (en)	2016-06-13	2019-04-17	Gilead Sciences, Inc.	Fxr (nr1h4) modulating compounds
CA2968836C (en)	2016-06-13	2025-09-02	Gilead Sciences, Inc.	FXR MODULATING COMPOUNDS (NR1H4)
IT201600068742A1 (it) *	2016-07-01	2018-01-01	Bar Pharmaceuticals Soc A Responsabilita Limitata	Derivati dell'acido iodesossicolico e loro uso
CN110121347A (zh)	2016-11-29	2019-08-13	英安塔制药有限公司	制备磺酰脲胆汁酸衍生物的方法
US10472386B2 (en)	2017-02-14	2019-11-12	Enanta Pharmaceuticals, Inc.	Bile acid derivatives as FXR agonists and methods of use thereof
EP4424364A3 (en)	2017-03-28	2024-11-27	Gilead Sciences, Inc.	Methods of treating liver disease
MX388300B (es) *	2017-04-07	2025-03-19	Enanta Pharm Inc	Proceso para la preparación de derivados de ácidos biliares de sulfonil carbamato
CN109021056B (zh) *	2017-06-09	2021-03-09	博瑞生物医药（苏州）股份有限公司	法尼酯x受体激动剂
CN109021055B (zh) *	2017-06-09	2021-04-09	博瑞生物医药（苏州）股份有限公司	Fxr激动剂
CN109021054B (zh) *	2017-06-09	2021-04-09	博瑞生物医药（苏州）股份有限公司	一种fxr激动剂
JP7308811B2 (ja) *	2017-07-26	2023-07-14	チアタイティエンチンファーマシューティカルグループカンパニーリミテッド	ステロイド系誘導体ｆｘｒアゴニストの製造方法
WO2019085963A1 (zh) *	2017-11-02	2019-05-09	正大天晴药业集团股份有限公司	一种胆酸类化合物的制备方法
AU2020209564B2 (en)	2019-01-15	2022-12-01	Gilead Sciences, Inc.	FXR (NR1H4) modulating compounds
CN118388474A (zh)	2019-02-19	2024-07-26	吉利德科学公司	Fxr激动剂的固体形式
WO2021071837A1 (en)	2019-10-07	2021-04-15	Kallyope, Inc.	Gpr119 agonists
CN112824425B (zh) *	2019-11-21	2023-10-03	成都西岭源药业有限公司	一种6-位烯基取代胆酸化合物及其制备方法和应用
BR112022017039A2 (pt)	2020-02-28	2022-11-16	Kallyope Inc	Agonistas de gpr40
IT202000008515A1 (it)	2020-04-21	2021-10-21	Bar Pharmaceuticals Soc A Responsabilita Limitata	Metodo per la sintesi di un derivato del colano
JP2023526625A (ja)	2020-05-19	2023-06-22	キャリーオペ，インク．	Ａｍｐｋアクチベーター
CN116390925A (zh)	2020-06-26	2023-07-04	卡尔优普公司	Ampk活化剂
IT202200011705A1 (it) *	2022-06-01	2023-12-01	Prec Bio Therapeutics S R L	Derivati del colesterolo e loro usi
WO2024006537A1 (en) *	2022-07-01	2024-01-04	Intercept Pharmaceuticals, Inc.	Methods for ameliorating cognitive impairment using bile acid derivatives
IT202200018669A1 (it)	2022-09-13	2024-03-13	Bar Pharmaceuticals Soc A Responsabilita Limitata	Combinazioni farmaceutiche comprendenti derivati del colano e loro usi
WO2024097247A1 (en) *	2022-10-31	2024-05-10	Intercept Pharmaceuticals, Inc.	Uses of farnesoid x receptor agonists
WO2024195903A1 (ko) *	2023-03-21	2024-09-26	경희대학교 산학협력단	신규한 콜린산 유도체 및 이의 용도
GB202314563D0 (en) *	2023-09-22	2023-11-08	Nzp Uk Ltd	Compounds
WO2025202883A1 (en) *	2024-03-25	2025-10-02	Bar Pharmaceuticals Societa' A Responsabilita' Limitata	Cholane derivatives for the treatment and the prevention of fxr and tgr5gp-bar1 receptors mediated diseases

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2326850T3 (es) *	1998-12-23	2009-10-20	Glaxo Group Limited	Ensayos para ligandos de receptores nucleares.
AU2002308295B2 (en) *	2001-03-12	2007-08-23	Intercept Pharmaceuticals, Inc.	Steroids as agonists for FXR
EP1568706A1 (en) *	2004-02-26	2005-08-31	Intercept Pharmaceuticals, Inc.	Novel steroid agonist for FXR
SI2712617T1 (sl) *	2004-03-12	2017-01-31	Intercept Pharmaceuticals, Inc.	Zdravljenje fibroze z uporabo Fxr ligandov
ITMI20050912A1 (it) *	2005-05-19	2006-11-20	Erregierre Spa	Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
EP2040713B1 (en) *	2006-06-27	2014-06-18	Intercept Pharmaceuticals Inc.	Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated deseases or conditions
US8940719B2 (en) *	2006-07-03	2015-01-27	Academia Sinica	Lithocholic acid analogues that inhibit sialyltransferase
FR2908310B1 (fr) *	2006-11-14	2009-07-10	Phytodia	Produits agonistes de tgr5 et leurs applications
CA2928178C (en) *	2007-01-19	2019-09-10	Intercept Pharmaceuticals, Inc.	Tgr5 modulators and methods of use thereof
EP1947108A1 (en) *	2007-01-19	2008-07-23	Intercept Pharmaceuticals, Inc.	TGR5 modulators and methods of use thereof
EP2324046B1 (en)	2008-07-30	2014-09-03	Intercept Pharmaceuticals, Inc.	Tgr5 modulators and methods of use thereof
EP3150620B1 (en) *	2008-11-19	2020-01-08	Intercept Pharmaceuticals, Inc.	Tgr5 modulators and methods of use thereof
NO2698375T3 (da) *	2008-11-19	2018-07-21
ES2552657T3 (es) *	2010-05-26	2015-12-01	Satiogen Pharmaceuticals, Inc.	Inhibidores del reciclado de ácidos biliares y saciógenos para el tratamiento de diabetes, obesidad, y afecciones gastrointestinales inflamatorias
WO2012047495A2 (en) *	2010-09-27	2012-04-12	Kythera Biopharmaceuticals, Inc.	Methods for preparing synthetic bile acids and compositions comprising the same
WO2013020108A2 (en) *	2011-08-04	2013-02-07	Lumena Pharmaceuticals, Inc.	Bile acid recycling inhibitors for treatment of pancreatitis
CA2877122C (en)	2012-06-19	2020-04-28	Intercept Pharmaceuticals, Inc.	Preparation, uses and solid forms of obeticholic acid
KR102068381B1 (ko) *	2012-10-26	2020-01-20	인터셉트 파마슈티컬즈, 인크.	담즙산 유도체의 제조 방법
US20140206657A1 (en) *	2013-01-18	2014-07-24	City Of Hope	Bile acid analog tgr5 agonists
CN103143021A (zh) *	2013-03-21	2013-06-12	中国药科大学	PPARα-UGT通路抑制剂在治疗炎性肠疾病中的应用
EP2997035B8 (en) *	2013-05-14	2018-05-23	Intercept Pharmaceuticals, Inc.	11-hydroxyl-6-substituted-derivatives of bile acids and amino acid conjugates thereof as farnesoid x receptor modulators
US9540415B2 (en) *	2013-08-01	2017-01-10	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Inhibitors of the farnesoid X receptor and uses in medicine
WO2015183794A1 (en) *	2014-05-27	2015-12-03	City Of Hope	Tgr5 agonist complexes for treating diabetes and cancer
EP3149019B1 (en)	2014-05-29	2019-12-04	Bar Pharmaceuticals S.r.l.	Cholane derivatives for use in the treatment and/or prevention of fxr and tgr5/gpbar1 mediated diseases
US20170233431A1 (en) *	2016-02-17	2017-08-17	City Of Hope	Bile acid derivatives and methods for synthesis and use

2015
- 2015-05-28 EP EP15731260.4A patent/EP3149019B1/en active Active
- 2015-05-28 EP EP19204247.1A patent/EP3626725B1/en active Active
- 2015-05-28 MX MX2016015724A patent/MX373721B/es active IP Right Grant
- 2015-05-28 JP JP2017514960A patent/JP6820253B2/ja active Active
- 2015-05-28 AU AU2015265893A patent/AU2015265893B2/en active Active
- 2015-05-28 PL PL19204247.1T patent/PL3626725T3/pl unknown
- 2015-05-28 PT PT192042471T patent/PT3626725T/pt unknown
- 2015-05-28 HU HUE19204247A patent/HUE061506T2/hu unknown
- 2015-05-28 HU HUE15731260A patent/HUE048351T2/hu unknown
- 2015-05-28 PT PT157312604T patent/PT3149019T/pt unknown
- 2015-05-28 EA EA201692316A patent/EA032820B1/ru unknown
- 2015-05-28 SG SG10201809362RA patent/SG10201809362RA/en unknown
- 2015-05-28 FI FIEP19204247.1T patent/FI3626725T3/fi active
- 2015-05-28 SI SI201531091T patent/SI3149019T1/sl unknown
- 2015-05-28 SM SM20230057T patent/SMT202300057T1/it unknown
- 2015-05-28 CN CN201910107511.6A patent/CN110003301B/zh active Active
- 2015-05-28 US US15/314,771 patent/US10407462B2/en active Active
- 2015-05-28 PL PL15731260T patent/PL3149019T3/pl unknown
- 2015-05-28 RS RS20200163A patent/RS59910B1/sr unknown
- 2015-05-28 DK DK15731260.4T patent/DK3149019T3/da active
- 2015-05-28 LT LTEP15731260.4T patent/LT3149019T/lt unknown
- 2015-05-28 DK DK19204247.1T patent/DK3626725T3/da active
- 2015-05-28 SM SM20200070T patent/SMT202000070T1/it unknown
- 2015-05-28 CN CN201580028528.2A patent/CN106661079B/zh active Active
- 2015-05-28 CA CA2948585A patent/CA2948585C/en active Active
- 2015-05-28 ES ES19204247T patent/ES2938874T3/es active Active
- 2015-05-28 HR HRP20230170TT patent/HRP20230170T1/hr unknown
- 2015-05-28 SI SI201531924T patent/SI3626725T1/sl unknown
- 2015-05-28 HR HRP20200225TT patent/HRP20200225T1/hr unknown
- 2015-05-28 SG SG11201609403UA patent/SG11201609403UA/en unknown
- 2015-05-28 LT LTEP19204247.1T patent/LT3626725T/lt unknown
- 2015-05-28 ES ES15731260T patent/ES2768718T3/es active Active
- 2015-05-28 MA MA39881A patent/MA39881B1/fr unknown
- 2015-05-28 RS RS20230132A patent/RS64050B1/sr unknown
- 2015-05-28 KR KR1020167034084A patent/KR102491556B1/ko active Active
- 2015-05-28 MX MX2020004024A patent/MX388957B/es unknown
- 2015-05-28 WO PCT/EP2015/061802 patent/WO2015181275A1/en not_active Ceased
2016
- 2016-11-22 PH PH12016502327A patent/PH12016502327A1/en unknown
2019
- 2019-08-01 US US16/529,571 patent/US11117926B2/en active Active
2020
- 2020-02-12 CY CY20201100131T patent/CY1122631T1/el unknown

Also Published As

Publication number	Publication date
WO2015181275A1 (en)	2015-12-03
EP3626725A1 (en)	2020-03-25
US10407462B2 (en)	2019-09-10
RS64050B1 (sr)	2023-04-28
MX373721B (es)	2020-04-20
EA201692316A1 (ru)	2017-03-31
PL3626725T3 (pl)	2023-04-03
MX2016015724A (es)	2017-07-11
FI3626725T3 (fi)	2023-03-16
SI3149019T1 (sl)	2020-03-31
WO2015181275A8 (en)	2016-02-18
MA39881B1 (fr)	2020-02-28
LT3626725T (lt)	2023-03-10
HRP20230170T1 (hr)	2023-03-31
KR102491556B1 (ko)	2023-01-25
MX2020004024A (es)	2021-12-10
EP3149019A1 (en)	2017-04-05
SG10201809362RA (en)	2018-11-29
CA2948585C (en)	2022-07-26
JP6820253B2 (ja)	2021-01-27
SI3626725T1 (sl)	2023-04-28
SG11201609403UA (en)	2016-12-29
ES2768718T3 (es)	2020-06-23
PT3149019T (pt)	2020-02-19
AU2015265893A1 (en)	2016-12-08
EP3626725B1 (en)	2022-11-30
US20170190731A1 (en)	2017-07-06
PT3626725T (pt)	2023-02-23
SMT202300057T1 (it)	2023-03-17
PL3149019T3 (pl)	2020-07-27
ES2938874T3 (es)	2023-04-17
SMT202000070T1 (it)	2020-03-13
JP2017516856A (ja)	2017-06-22
RS59910B1 (sr)	2020-03-31
PH12016502327A1 (en)	2017-02-06
EA032820B1 (ru)	2019-07-31
CA2948585A1 (en)	2015-12-03
HUE048351T2 (hu)	2020-07-28
CN106661079A (zh)	2017-05-10
CN110003301B (zh)	2022-06-10
CN110003301A (zh)	2019-07-12
LT3149019T (lt)	2020-02-25
AU2015265893B2 (en)	2020-11-12
BR112016028085A2 (pt)	2017-08-22
DK3626725T3 (da)	2023-02-27
US11117926B2 (en)	2021-09-14
KR20170008767A (ko)	2017-01-24
HUE061506T2 (hu)	2023-07-28
EP3149019B1 (en)	2019-12-04
CN106661079B (zh)	2019-03-01
HRP20200225T1 (hr)	2020-05-29
MX388957B (es)	2025-03-20
US20190352328A1 (en)	2019-11-21
CY1122631T1 (el)	2021-03-12

Publication	Publication Date	Title
DK3149019T3 (da)	2020-02-17	Cholan-derivater til anvendelse ved behandling og/eller forebyggelse af FXR- og TGR5/GPBAR1-formidlede sygdomme
DK3102673T3 (da)	2020-07-06	Fremgangsmåder og sammensætninger til behandling af beta-talassæmi
DK3206686T3 (da)	2019-12-16	Gamma-diketoner til behandling og forebyggelse af ældning af huden og rynker
DK3227262T3 (da)	2020-08-10	Sulfidalkyl og pyridyl-revers-sulfonamidforbindelser til hbv-behandling
DK3402888T3 (da)	2020-11-30	Middel og fremgangsmåder til behandling af hbv
DK3096798T3 (da)	2021-03-01	Plasmakallikreinbindende proteiner og anvendelser deraf til behandling af hereditært angioødem
DK3481846T3 (da)	2021-08-16	11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande
DK3504187T3 (da)	2025-04-14	Anvendelse af pridopidin til behandling af funktionel tilbagegang
DK3240612T3 (da)	2021-01-18	Fremgangsmåder til behandling af nethindesygdomme
DK3185957T3 (da)	2022-08-29	Patisiran til anvendelse ved behandlingen af transthyretin-medieret amyloidosis
DK3242947T3 (da)	2020-08-03	Genterapi og elektroporese til behandling af maligniteter
DK3303339T3 (da)	2021-04-12	Pde9-inhibitorer med imidazotriazinonskelet og imidazopyrazinonskelet til behandling af perifere sygdomme
DK3395353T5 (da)	2024-09-30	Plasminogen til anvendelse til behandling eller forebyggelse af diabetes-mellitus-nerveskade
DK3183010T3 (da)	2020-10-12	Anordning og tilhørende fremgangsmåde til behandling af medicinsk affald
DK3209696T3 (da)	2021-08-09	Fremgangsmåder og sammensætninger til diagnosticering og behandling af glioblastom
DK3189074T3 (da)	2021-04-19	Sammensætninger og metoder til behandling og forebyggelse af inflammation
DK3362449T3 (da)	2021-07-19	Sibirilin-derivater til anvendelse til at forebygge og/eller behandle lidelser associeret med cellulær nekroptose
BR112016022976A2 (pt)	2017-08-15	Métodos para o tratamento de hcv
DK3157531T3 (da)	2021-07-05	Fremgangsmåder og sammensætninger til stimulering af det intestinale enteroendokrinesystem til behandling af sygdomme eller tilstande relateret hertil
DK3164123T3 (da)	2020-08-03	Hidtil ukendte anvendelser af benzylidenguanidinderivater til behandling af proteopatier
DK3191103T3 (da)	2021-09-27	Sammensætninger og fremgangsmåder til behandling af præcancerøse hudlæsioner
DK3149049T3 (da)	2023-01-23	Il-22 til anvendelse til behandling af stofskiftesygdomme
DK3110446T3 (da)	2022-02-28	Fremgangsmåder og sammensætninger til behandling af Siglec-8-associerede sygdomme
DK3261642T3 (da)	2021-08-09	Quinolinderivater til anvendelse ved behandling eller forebyggelse af virusinfektioner
DK3151943T3 (da)	2021-03-22	Filterpanel og fremgangsmåde til fremstilling heraf